Stephen M. Hahn, MD, Confirmed as FDA Commissioner

Stephen M. Hahn, MD, from The University of Texas MD Anderson Cancer Center, has been nominated by President Donald Trump and confirmed as Commissioner of the FDA.

FDA Approves Enzalutamide for mCSPC Treatment

The FDA approved a supplemental new drug application for enzalutamide (Xtandi) to treat men with metastatic castration-sensitive prostate cancer.

ICYMI: Pembrolizumab Plus Lenvatinib Approved for Endometrial Cancer

The FDA approved the use of pembrolizumab in combination with lenvatinib for endometrial cancer.

Proven portfolio of tests + services, that’s our Foundation.

Our portfolio of genomic tests & services is designed for cancer patients at any line of therapy, with proven utility for clinical decision making. Rx only; advanced cancer; doesn’t guarantee treatment match.

Learn more